Skip to content
Who We Serve
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees
About Us
Our Team
Our Story
Investment Strategies
Who We Serve
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees
About Us
Our Team
Our Story
Investment Strategies
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees (911 Financial Services™)
Our Story
Our Team
Investment Strategies
Contact Us
Schwab Client Login
Private Wealth
Firefighters (FirefightersUnited™)
Police (911 Financial Services™)
Government Employees (911 Financial Services™)
Our Story
Our Team
Investment Strategies
Contact Us
Schwab Client Login
Contact Us
Schwab Client Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Instil Bio, Inc.
(NQ:
TIL
)
6.350
+0.440 (+7.45%)
Delayed Quote
Updated: 9:42 AM EDT, Oct 19, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Instil Bio, Inc.
< Previous
1
2
Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
February 03, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
January 27, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
January 20, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Instil Bio, Inc. - TIL
January 13, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)
September 10, 2025
From
Instil Bio
Via
GlobeNewswire
Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 13, 2025
From
Instil Bio
Via
GlobeNewswire
ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China
July 31, 2025
From
Instil Bio
Via
GlobeNewswire
Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors
July 02, 2025
From
Instil Bio
Via
GlobeNewswire
Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program
June 11, 2025
From
Instil Bio
Via
GlobeNewswire
Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer
June 02, 2025
From
Instil Bio
Via
GlobeNewswire
Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference
May 30, 2025
From
Instil Bio
Via
GlobeNewswire
Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago
May 23, 2025
From
Instil Bio
Via
GlobeNewswire
Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated
May 22, 2025
From
Instil Bio
Via
GlobeNewswire
Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 13, 2025
From
Instil Bio
Via
GlobeNewswire
Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
March 04, 2025
From
Instil Bio
Via
GlobeNewswire
Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody
January 14, 2025
From
Instil Bio
Via
GlobeNewswire
Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 13, 2024
From
Instil Bio
Via
GlobeNewswire
Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer
September 16, 2024
From
Instil Bio
Via
GlobeNewswire
Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 13, 2024
From
Instil Bio
Via
GlobeNewswire
Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody
August 01, 2024
From
Instil Bio
Via
GlobeNewswire
Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 10, 2024
From
Instil Bio
Via
GlobeNewswire
Instil Bio Announces Strategic Update
January 16, 2024
From
Instil Bio
Via
GlobeNewswire
Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split
December 05, 2023
From
Instil Bio
Via
GlobeNewswire
Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 13, 2023
From
Instil Bio
Via
GlobeNewswire
Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting
November 06, 2023
Presented novel preclinical data showing that CoStAR enhances activity of CD4+ T cells in multiple ways to broaden anti-tumor response and support CD8+ T cells
From
Instil Bio
Via
GlobeNewswire
Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 14, 2023
From
Instil Bio
Via
GlobeNewswire
Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference
June 26, 2023
From
Instil Bio
Via
GlobeNewswire
Instil Bio Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 11, 2023
From
Instil Bio
Via
GlobeNewswire
Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 31, 2023
From
Instil Bio
Via
GlobeNewswire
NASDAQ:TIL Shareholder Notice: Investigation over Potential Wrongdoing at Instil Bio, Inc.
↗
February 10, 2023
San Diego, CA -- (SBWIRE) -- 02/10/2023 -- Certain directors of Instil Bio, Inc. are under investigation over potential breaches of fiduciary duties.
Via
SBWire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
